Article Details
Retrieved on: 2022-06-03 19:21:03
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Daiichi Sankyo licensed its two most advanced antibody-drug conjugates to Astrazeneca – Enhertu and datopotamab deruxtecan – but it has kept a ...
Article found on: www.evaluate.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here